Dear Editor,

Although the interaction between TB and COVID-19 is unclear, recent evidence suggests that COVID-19 could worsen the outcome of active pulmonary TB or aggravate respiratory sequelae, especially in settings with high levels of TB infection.1–4 The immunosuppressive and anti-inflammatory therapies for COVID-19 aim to contain tissue damage induced by the cytokine storm.5–8 For example, guidelines on the treatment and management of patients with COVID-19 recommend the use of corticosteroids (dexamethasone) in hospitalised patients with severe disease and dexamethasone and other immunomodulatory drugs such as tocilizumab, an interleukin 6 receptor antagonist, in critically ill patients.9 Although immunosuppressive therapies for COVID-19 are generally short-lived, the risk of activation of TB infection (TBI) should be kept in mind. Screening for TBI may thus be useful in patients with severe COVID-19, especially in high-resource countries. Among interferon-gamma release assays (IGRAs), the QuantiFERON-TB Gold Plus (QFT-Plus; Qiagen, Hilden, Germany) test is based on the levels of interferon-gamma (IFN-γ) released by a CD4+ and CD8+ T-cell-mediated immune response after in vitro stimulation of human whole-blood by antigens specific to the Mycobacterium tuberculosis complex. Furthermore, the QFT-Plus assay includes a mitogen-based control designed non-specifically to elicit a T-cell response, and thus assess the immunological fitness of the patient. QFT-Plus assay results could therefore be affected by conditions responsible for immune dysregulation. IGRAs have been performed in many hospitalised patients with COVID-19 to rule out TBI before prescribing anti-inflammatory and immunosuppressive treatments, but this has not been systematic. Some studies have reported that the QFT-Plus test had a high and unexpected rate of indeterminate results in COVID-19 patients with severe lung disease.10–12 The primary aim of this study is to describe the results of the IGRA test among patients with severe COVID-19 who were eligible for immunosuppressive therapies and admitted to a referral hospital in Bologna, Northern Italy. We also assessed the prevalence, clinical impact and factors associated with indeterminate QFT-Plus result in the study population.

We conducted a retrospective, monocentric study enrolling hospitalised adult patients with COVID-19 who underwent QFT-Plus testing between 1 October and 25 November 2020. This study was approved by the Ethic Committee of Area Vasta Emilia Centro (AVEC), Bologna, Italy (Protocol code n. 550/2020/Oss/AOUBo). All patients enrolled had a positive nasopharyngeal swab for SARS CoV-2 using real-time polymerase chain reaction. All subjects with incomplete clinical and laboratory data have been excluded. We collected the following data on each individual: demographics, comorbidities, previous exposure to immunosuppressive therapies, date of onset of COVID-19 symptoms, COVID-19 diagnosis date, date of admission, need of intensive care, steroid or other immunosuppressive therapy administered for COVID-19, laboratory data at admission, date and result of QFT-Plus and outcome (death, survival). The QFT-Plus test was carried out using the chemiluminescence immunoassay method per the manufacturer instructions.13 Test results were expressed in quantitative and qualitative terms (positive, negative and indeterminate) in accordance with the manufacturer’s algorithms. Continuous variables were expressed as mean ± standard deviation or median with interquartile range as appropriate, and categorical variables were expressed as percentages. Comparisons between two groups were made using the Mann–Whitney U-test for continuous variables, and the χ² or Fisher test for categorical variables. P ≤ 0.05 was considered statistically significant. All the analyses were conducted using SPSS v25 (IBM Corp, Armonk, NY, USA).

Of a total of 676 patients hospitalised due to COVID-19 during this period, 268 (39.6%) subjects have been enrolled. The mean age was 68.6 ± 15.0 years; 69.0% were males, 86.6% were born in Italy. Among these, 209 (78.0%) had a determinate QFT-plus result: 199/209 (95.2%) had a negative result and 10/209 (4.7%) were positive; 59/268 had indeterminate test results (22.0%), all of whom showed a lack of response to mitogen control. Study population characteristics according to QFT-Plus results are shown in the Table. The demographic variables, comorbidities, previous immunosuppressive therapy, time between symptoms onset and QFT-Plus and time between admission and QFT-plus testing were not correlated with the indeterminate outcome. A significant correlation (P = 0.033) was found between the use of corticosteroids for COVID-19 and an indeterminate QFT-Plus result.

BG and FB contributed equally to this work.
The longer the duration of corticosteroid therapy before the QTF-Plus, the higher the probability of having an indeterminate result ($P = 0.015$) (Table and Figure). Indeterminate results were also associated with baseline lymphocytes count ($P = 0.000$), ferritin ($P = 0.001$), lactate dehydrogenase ($LDH, P = 0.000$), severity of COVID-19 disease (expressed in terms of ratio of arterial oxygen partial pressure ($PaO_2$ in mmHg) to fractional inspired oxygen ($PaO_2/FiO_2$) < 100, $P = 0.015$), need of intensive care ($P = 0.005$) and negative outcome (death, $P = 0.016$).

Our study confirms a high rate of indeterminate QTF-Plus outcome in COVID-19 patients (22%). In healthy populations and in pre-pandemic conditions, indeterminate results occurred on average in approximately 2–11% of the tests in similar low-burden settings. Other studies have reported even higher indeterminate rates among COVID-19 patients, up to 40.3%. In our experience, immune dysregula-

### Table: Study population characteristics disaggregated by QFT-Plus result

|                        | Total n | QFT-Plus indeterminate n (%) | QFT-Plus determinate n (%) | $P$ value | OR (95% CI) |
|------------------------|---------|-----------------------------|-----------------------------|-----------|-------------|
| Total                  | 268     | 59 (22.0)                   | 209 (78.0)                  |           |             |
| Sex                    |         |                             |                             |           |             |
| Male                   | 185     | 39 (21.1)                   | 146 (78.9)                  | 0.582     | 0.841 (0.455–1.556) |
| Female                 | 83      | 20 (24.1)                   | 63 (75.9)                   |           |             |
| Age, years, mean ± SD  | 68.6 ± 15.0 | 71.0 ± 14.4 | 67.9 ± 15.2 | 0.166     |             |
| Age groups, years      |         |                             |                             |           |             |
| <65                    | 105     | 18 (17.1)                   | 87 (82.9)                   | 0.122     | 1.624 (0.875–3.015) |
| >65                    | 163     | 41 (25.2)                   | 122 (74.8)                  |           |             |
| Origin                 |         |                             |                             | 0.206     | 1.881 (0.679–5.074) |
| Italian                | 232     | 54 (23.3)                   | 178 (76.7)                  |           |             |
| Foreign-born           | 36      | 5 (13.9)                    | 31 (86.1)                   |           |             |
| Comorbidities          |         |                             |                             | 0.250     | 0.649 (0.338–1.245) |
| Haematological disease | 14      | 2 (14.3)                    | 12 (85.7)                   | 0.550     | 0.769 (0.153–3.858) |
| Malignancies           | 6       | 0 (0)                       | 6 (100)                     | 0.584     | 0.917 (0.855–0.983) |
| HIV infection          | 1       | 0 (0)                       | 1 (100)                     | 0.828     | 0.986 (0.959–1.014) |
| Chronic renal failure  | 26      | 4 (15.4)                    | 22 (84.6)                   | 0.516     | 0.826 (0.237–2.883) |
| Diabetes               | 48      | 9 (18.8)                    | 39 (81.2)                   | 0.898     | 1.269 (0.409–3.938) |
| Transplant recipient   | 4       | 0 (0)                       | 4 (100)                     | 0.462     | 0.944 (0.893–0.999) |
| Other                  | 12      | 3 (25.0)                    | 9 (75.0)                    | 0.340     | 1.750 (0.413–7.424) |
| Chronic immuno-suppressive treatment |         |                             |                             | 0.932     | 1.046 (0.369–2.964) |
| Yes                    | 22      | 5 (22.7)                    | 17 (77.3)                   |           |             |
| No                     | 246     | 54 (22.0)                   | 192 (78.0)                  |           |             |
| Steroid treatment before QFT-Plus |         |                             |                             | 0.033     |             |
| Yes                    | 217     | 53 (24.4)                   | 164 (75.6)                  |           |             |
| No                     | 51      | 6 (11.8)                    | 45 (88.2)                   |           |             |
| Steroid start          | 244     |                             |                             | 0.015     |             |
| 0–1 days before QFT-Plus | 55    | 10 (18.2)                   | 45 (81.8)                   |           |             |
| 1.1–2 days before QFT-Plus | 67    | 12 (17.9)                   | 55 (82.1)                   |           |             |
| >2 days before QFT-Plus | 95     | 31 (32.6)                   | 64 (67.4)                   |           |             |
| After QTF-Plus         | 27      | 2 (7.4)                     | 25 (92.6)                   |           |             |
| Time between symptoms onset and QFT-Plus, days (range) | 8 (6–11) | 8 (5–11) | 0.460     |             |
| Time between admission and QFT-Plus, days (range) | 1 (1–3) | 1 (1–2) | 0.430     |             |
| Admission in intensive care unit |         |                             |                             | 0.005     | 2.775 (1.534–5.019) |
| Yes                    | 107     | 35 (32.7)                   | 72 (67.3)                   |           |             |
| No                     | 161     | 24 (14.9)                   | 137 (85.1)                  |           |             |
| Outcome                |         |                             |                             | 0.016     | 2.167 (1.143–4.108) |
| Survival               | 208     | 39 (18.7)                   | 169 (81.3)                  |           |             |
| Death                  | 60      | 20 (33.3)                   | 40 (66.7)                   |           |             |
| Laboratory data (range) |        |                             |                             |           |             |
| Lymphocytes, x10⁹/L    | 264     | 0.64 (0.45–1.04)            | 1.05 (0.74–1.46)            | 0.000     |             |
| IL-6, pg/ml            | 230     | 49.3 (13.1–109.4)           | 37.4 (17.5–70.4)            | 0.390     |             |
| Ferritin, ng/ml        | 239     | 644.5 (351.5–1152.0)        | 398.0 (222.5–775.0)         | 0.001     |             |
| LDH, U/L               | 257     | 383.0 (299.0–458.0)         | 285.5 (230.2–384.2)         | 0.000     |             |
| PaO₂/FiO₂              | 253     | 181.5 (121.0–260.5)         | 249.0 (176.0–321.0)         | 0.000     |             |
| Disease severity       |         |                             |                             | 0.015     |             |
| PaO₂/FiO₂ < 100        | 21      | 8 (38.1)                    | 13 (61.9)                   |           |             |
| PaO₂/FiO₂ > 100        | 232     | 48 (20.7)                   | 184 (79.3)                  |           |             |

* Including 27 cases who started steroid treatment only after performing the QFT-Plus test and 24 cases who did not receive corticosteroid therapy.

QFT = QuantIFERON; OR = odds ratio; CI = confidence interval; SD = standard deviation; IL = interleukin; LDH = lactate dehydrogenase; PaO₂ = partial pressure of oxygen; FiO₂ = fractional oxygen.
tion due to the coexistence of immunosuppressive conditions (such as diabetes or haematological diseases or malignancies) do not seem to influence the QFT-Plus result. Similarly, in this study, the chronic use of corticosteroid or other immunosuppressant therapies was not associated with a higher risk of indeterminate QFT-Plus results than in the study population (22.7% vs. 22.0%, respectively). Instead, a significant correlation with the use of corticosteroid therapy due to COVID-19 disease emerged, especially when steroid use was started ≥1 day before the QFT-Plus test was performed. To note, indeterminate result occurred also among those who did not receive corticosteroid therapy during hospitalisation (4/24, 16.7%) or those who started steroid treatment only after the QFT-Plus test (2/27, 7.4%). Hence, we can hypothesise that COVID-19 and its pathogenetic process play a direct role in reducing response to mitogen and influencing QFT-Plus outcome. As SARS-CoV-2 leads to a decrease in the number of lymphocytes, the level of IFN-γ released by CD4+ T-cells is anticipated to be lower in severe cases. It was also found that patients with indeterminate outcomes had more severe hypoxemia than patients with determinate results, with considerably lower PaO₂/FiO₂ values, used as proxy for the severity of respiratory failure. As reported by other studies, indeterminate results were correlated with the need for intensive care and death, which supports the hypothesis that disease severity and test outcome were correlated.

In conclusion, our data confirm the occurrence of high rates of QTF-Plus-indeterminate results among hospitalised COVID-19 patients, and suggest that SARS-CoV-2, combined with the use of corticosteroid drugs, are main risk factors. Our findings cast doubt on the usefulness of IGRA tests in immunosuppressive pre-treatment screening of COVID-19 patients. However, indeterminate QTF-Plus results may help predict the severity and mortality of COVID-19 disease. Other studies are needed to confirm these hypotheses.

B. GRANOZZI, F. BISOGNIN, M. TADOLINI, G. LOMBARDI, E. ZANGOLI, D. SALVI, A. DORMI, P. DAL MONTE

1 Infectious Diseases Unit, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Azienda Ospedaliero, Universitaria di Bologna, Bologna, 2 Department of Medical and Surgical Sciences, Alma Mater Studiorum University of Bologna, Bologna, 3 Microbiology Unit, IRCCS Azienda Ospedaliero, Universitaria di Bologna, Bologna, 4 Department of Experimental, Diagnostic and Specialty Medicine, Alma Mater Studiorum University of Bologna, Bologna, 5 Respiratory and Critical care Unit, IRCCS Azienda Ospedaliero, Universitaria di Bologna, Bologna, 6 Digestive Endoscopy Unit and Gastroenterology, Fondazione Poliambulanza, Brescia, 7 Digestive Endoscopy Unit, Catholic University of the Sacred Heart, Rome, Italy

Correspondence to: Marina Tadolini, Infectious Diseases Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Via Massarenti 9, 40138 Bologna, Italy. E-mail: marina.tadolini@unibo.it; mtadolini@hotmail.com

Conflicts of interest: none declared.

This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

References

1 Tadolini M, et al. Active tuberculosis, sequelae and COVID-19
co-infection: first cohort of 49 cases. Eur Respir J 2020;56(1):2001398.
2 Tamuzi JL, et al. Implications of COVID-19 in high burden countries for HIV/TB: a systematic review of evidence. BMC Infect Dis 2020;20(1):744.
3 Sy KTL, et al. Previous and active tuberculosis increases risk of death and prolongs recovery in patients with COVID-19. Infect Dis 2020;52(12):902–907.
4 Stochino C, et al. Clinical characteristics of COVID-19 and active tuberculosis co-infection in an Italian reference hospital. Eur Respir J 2020;56(1):2001708.
5 Jamal M, et al. Immune dysregulation and system pathology in COVID-19. Virulence 2021;12(1):918–936.
6 Siddiqi HK, et al. COVID-19 illness in native and immunosuppressed states: A clinical-therapeutic staging proposal. J Heart Lung Transplant 2020;39(5):405–407.
7 World Health Organization. COVID-19 clinical management: living guidance, 2021. Geneva, Switzerland: WHO, 2021. WHO/2019-nCoV/clinical/2021.2 [Last access 20 May 2022].
8 COVID-19 Treatment Guidelines Panel. Coronavirus disease 2019 (COVID-19) treatment guidelines. National Institutes of Health, 2022. https://www.covid19treatmentguidelines.nih.gov/ [Accessed May 2022].
9 Bhimraj A, et al. Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19. Version 8.0.0. Arlington, VA, USA: Infectious Diseases Society of America, 2022.
10 Sánchez-Martínez F, et al.; COVID-19 Infectious Disease Team Hospital del Mar. Influence of cytokine release syndrome in severe COVID-19 patients treated with tocilizumab over the QuantiFERON-TB Gold Plus results. Arch Bronconeumol 2021;57(Suppl 2):38–39.
11 Solanich X, et al. Clinical significance of indeterminate QuantiFERON-TB Gold Plus assay results in hospitalized COVID-19 patients with severe hyperinflammatory syndrome. J ClinMed 2021;10(5):918.
12 Torre A, et al. Preliminary observations on IGRA testing for TB infection in patients with severe COVID-19 eligible for immunosuppressive therapy. Respir Med 2020;175:106204.
13 Qiagen. DiaSorin LIAISON QuantiFERON-TB Gold Plus. Hilden, Germany: Qiagen, 2019. https://www.quantiferon.com/products/liaison-quantiferon-tb-gold-plus/ [Accessed May 2022].
14 Brown J, et al. Frequency and significance of indeterminate and borderline QuantiFERON Gold TB IGRA results. Eur Respir J 2017;50:1701267.
15 Diao B, et al. Reduction and functional exhaustion of T cells in patients with Coronavirus disease 2019 (COVID-19). Front Immunol 2020;11:827.